[Market Feature] Daiwha Pharmaceutical Surges on News of Chinese Approval for Alzheimer’s-Type Dementia Treatment

Daiwha Pharmaceutical is showing strong performance. This is believed to be due to the news that its Alzheimer’s-type dementia treatment has received approval in China.

As of 2:00 p.m. on September 22, Daiwha Pharmaceutical was trading at 17,090 won, up 18.61% from the previous day.

On this day, Daiwha Pharmaceutical announced that it had received approval in China for its Alzheimer’s-type dementia treatment, Rivamensa Patch (active ingredient: rivastigmine), through its joint venture JHK Biopharm (based in Shanghai, China, with Daiwha Pharmaceutical holding a 25% stake).

This approval marks the first case of a transdermal drug delivery system (TDDS) patch product developed by a Korean pharmaceutical company being approved in China.

The number of dementia patients in China is estimated to exceed 10 million, and this figure is expected to rise to over 40 million by 2050. Accordingly, demand for treatments for Alzheimer’s-type and other forms of dementia is expected to continue increasing. Rivamensa Patch offers key advantages such as convenient administration in patch form, minimized skin irritation, and prevention of drug leakage through improved adhesion.